Trends in New Oncology Target Treatments

By 2035, it is estimated that 24 million cancer cases will occur on an annual basis. Although recent progress has deepened our understanding of the disease and has also brought on unprecedented new possibilities for personalized medicine, there are still many cancer types for which there are no, or minimally, effective therapy. Producing new effective cancer treatments thus is seriously needed to keep pace with the growing prevalence but the task is a very difficult and costly one, averaging about $1-2 billion to develop a single drug and requiring vested interests by many stakeholders. Where are investors, companies and investigators placing current bets? This panel will conduct a deep-dive on recent advances in oncology drug development, with a focus on new targets as well as new ways of targeting. Officers from leading companies will provide their insights on the most exciting developments.